Vascor
Vascor - General Information
A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem]
Pharmacology of Vascor
Vascor is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.
Vascor for patients
Vascor Interactions
Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris. Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina. Available data are not sufficient, however, to predict the effects of concomitant medication on patients with impaired ventricular function or cardiac conduction abnormalities.
Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations. Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels. Available data are neither sufficient to rule out possible increases in serum digoxin with concomitant treatment in some patients, nor other possible interactions, particularly in patients with cardiac conduction abnormalities (Also see WARNINGS Congestive Heart Failure).
Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
General Interactions: Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride. In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants. Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride. Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
Vascor Contraindications
VASCOR (bepridil hydrochloride) is contraindicated in patients with a known sensitivity to bepridil hydrochloride.
VASCOR is contraindicated in (1) patients with a history of serious ventricular arrhythmias, (2) patients with sick sinus syndrome or patients with second- or third-degree AV block, except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm Hg systolic), (4) patients with uncompensated cardiac insufficiency, (5) patients with congenital QT interval prolongation, and (6) patients taking other drugs that prolong QT interval.
Additional information about Vascor
Vascor Indication: For the treatment of chronic stable angina (classic effort-associated angina).
Mechanism Of Action: Vascor has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Vascor inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Vascor regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
Drug Interactions: Amprenavir Amprenavir increases the effect and toxicity of bepridil
Astemizole Increased risk of cardiotoxicity and arrhythmias
Atazanavir Atazanavir increases the effect and toxicity of bepridil
Cisapride Increased risk of cardiotoxicity and arrhythmias
Gatifloxacin Increased risk of cardiotoxicity and arrhythmias
Fosamprenavir Amprenavir increases the effect and toxicity of bepridil
Grepafloxacin Increased risk of cardiotoxicity and arrhythmias
Levofloxacin Increased risk of cardiotoxicity and arrhythmias
Moxifloxacin Increased risk of cardiotoxicity and arrhythmias
Ritonavir Ritonavir increases the effect and toxicity of bepridil
Sparfloxacin Increased risk of cardiotoxicity and arrhythmias
Terfenadine Increased risk of cardiotoxicity and arrhythmias
Food Interactions: Take with food to reduce nausea.
Generic Name: Bepridil
Synonyms: Bepadin
Drug Category: Vasodilator Agents; Antihypertensive Agents; Antiarrhythmic Agents; Calcium Channel Blockers
Drug Type: Small Molecule; Approved
Other Brand Names containing Bepridil: Vascor;
Absorption: Rapidly and completely absorbed after oral administration.
Toxicity (Overdose): There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
Protein Binding: 99%
Biotransformation: Hepatic.
Half Life: 24-50 hours
Dosage Forms of Vascor: Tablet, film coated Oral
Chemical IUPAC Name: N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]-N-(phenylmethyl)aniline
Chemical Formula: C24H34N2O
Bepridil on Wikipedia: https://en.wikipedia.org/wiki/Bepridil
Organisms Affected: Humans and other mammals